Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?

FRANCESCO FANFANI, ANNA FAGOTTI, ALFREDO ERCOLI, VALERIO GALLOTTA, VITO CHIANTERA, STEFANO RESTAINO, GIORGIA MONTEROSSI and GIOVANNI SCAMBIA
Anticancer Research December 2015, 35 (12) 6951-6955;
FRANCESCO FANFANI
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: francesco.fanfani@rm.unicatt.it
ANNA FAGOTTI
2Minimally Invasive Gynecology, St. Maria Hospital, University of Perugia, Terni, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALFREDO ERCOLI
3Gynecologic Oncology Unit, Policlinico Abano Terme, Abano Terme, Padua, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VALERIO GALLOTTA
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VITO CHIANTERA
4Division of Gynaecologic Oncology, Foundation John Paul II, Campobasso, Italy, Department of Obstetrics and Gynaecology, University of Molise, Campobasso, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFANO RESTAINO
5Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, University of Trieste, Trieste, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIORGIA MONTEROSSI
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIOVANNI SCAMBIA
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 35 no. 12 6951-6955
PubMed 
26637921

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received August 7, 2015
  • Revision received September 9, 2015
  • Accepted September 16, 2015
  • Published online December 5, 2015.

Copyright & Usage 
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. FRANCESCO FANFANI1⇑,
  2. ANNA FAGOTTI2,
  3. ALFREDO ERCOLI3,
  4. VALERIO GALLOTTA1,
  5. VITO CHIANTERA4,
  6. STEFANO RESTAINO5,
  7. GIORGIA MONTEROSSI1 and
  8. GIOVANNI SCAMBIA1
  1. 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy
  2. 2Minimally Invasive Gynecology, St. Maria Hospital, University of Perugia, Terni, Italy
  3. 3Gynecologic Oncology Unit, Policlinico Abano Terme, Abano Terme, Padua, Italy
  4. 4Division of Gynaecologic Oncology, Foundation John Paul II, Campobasso, Italy, Department of Obstetrics and Gynaecology, University of Molise, Campobasso, Italy
  5. 5Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, University of Trieste, Trieste, Italy
  1. Correspondence to: Francesco Fanfani, MD, Gynecologic Oncology Unit, Dept. of Obstetrics and Gynecology, Catholic University of the Sacred Hearth, Rome, Italy. Tel/Fax: +39 0635508736, e-mail: francesco.fanfani{at}rm.unicatt.it
View Full Text

Cited By...

  • 15 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (12)
Anticancer Research
Vol. 35, Issue 12
December 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?
FRANCESCO FANFANI, ANNA FAGOTTI, ALFREDO ERCOLI, VALERIO GALLOTTA, VITO CHIANTERA, STEFANO RESTAINO, GIORGIA MONTEROSSI, GIOVANNI SCAMBIA
Anticancer Research Dec 2015, 35 (12) 6951-6955;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?
FRANCESCO FANFANI, ANNA FAGOTTI, ALFREDO ERCOLI, VALERIO GALLOTTA, VITO CHIANTERA, STEFANO RESTAINO, GIORGIA MONTEROSSI, GIOVANNI SCAMBIA
Anticancer Research Dec 2015, 35 (12) 6951-6955;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Complete tumor resection and demonstration of detailed anatomy of the porta hepatis in a patient with recurrent epithelial ovarian cancer
  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
  • Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • recurrent ovarian cancer
  • tertiary cytoreduction
  • quaternary cytoreduction
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire